The estimated Net Worth of Takashi Kei Kishimoto is at least $372 Thousand dollars as of 4 January 2023. Dr Kishimoto owns over 9,784 units of Selecta Biosciences Inc stock worth over $320,598 and over the last 8 years he sold SELB stock worth over $51,764.
Dr has made over 8 trades of the Selecta Biosciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 9,784 units of SELB stock worth $11,056 on 4 January 2023.
The largest trade he's ever made was exercising 36,114 units of Selecta Biosciences Inc stock on 7 January 2019 worth over $100,036. On average, Dr trades about 5,055 units every 100 days since 2016. As of 4 January 2023 he still owns at least 364,316 units of Selecta Biosciences Inc stock.
You can see the complete history of Dr Kishimoto stock trades at the bottom of the page.
Dr. Takashi Kei Kishimoto Ph.D. is the Chief Scientific Officer at Selecta Biosciences Inc.
Dr D is 61, he's been the Chief Scientific Officer of Selecta Biosciences Inc since . There are 6 older and 10 younger executives at Selecta Biosciences Inc. The oldest executive at Selecta Biosciences Inc is Patrick Zenner, 73, who is the Independent Director.
Takashi's mailing address filed with the SEC is C/O SELECTA BIOSCIENCES, INC., 65 GROVE STREET, WATERTOWN, MA, 02472.
Over the last 8 years, insiders at Selecta Biosciences Inc have traded over $10,638,154 worth of Selecta Biosciences Inc stock and bought 37,612,684 units worth $162,669,477 . The most active insiders traders include Timothy A Springer, Advisors Llc Orbi Med Capit..., and Carl L Gordon. On average, Selecta Biosciences Inc executives and independent directors trade stock every 23 days with the average trade being worth of $300,312. The most recent stock trade was executed by Carsten Brunn on 25 September 2023, trading 2,932 units of SELB stock currently worth $3,108.
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
Selecta Biosciences Inc executives and other stock owners filed with the SEC include: